Actively Recruiting
Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
Led by Chang Gung Memorial Hospital · Updated on 2025-12-22
100
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.
CONDITIONS
Official Title
Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 and 90 years
- Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC)
- Completed surgical treatment and identified as having high-risk factors, followed by concurrent chemoradiotherapy
- Willing to continue follow-up visits at the hospital after completion of treatment
You will not qualify if you...
- Presence of psychiatric disorders
- Deemed unsuitable for participation by the attending physician
- Unwilling to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Linkou Chang Gung Memorial Hospital
Taoyuan City, Taiwan, 333423
Actively Recruiting
Research Team
C
ChunTa Liao, PhD
CONTACT
C
Chia-Hsun Hsieh, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here